title: Gene expression in cerebral ischemia: a new approach for neuroprotection.
abstract: Cerebral ischemia is one of the strongest stimuli for gene induction in the brain. Hundreds of genes have been found to be induced by brain ischemia. Many genes are involved in neurodestructive functions such as excitotoxicity, inflammatory response and neuronal apoptosis. However, cerebral ischemia is also a powerful reformatting and reprogramming stimulus for the brain through neuroprotective gene expression. Several genes may participate in both cellular responses. Thus, isolation of candidate genes for neuroprotection strategies and interpretation of expression changes have been proven difficult. Nevertheless, many studies are being carried out to improve the knowledge of the gene activation and protein expression following ischemic stroke, as well as in the development of new therapies that modify biochemical, molecular and genetic changes underlying cerebral ischemia. Owing to the complexity of the process involving numerous critical genes expressed differentially in time, space and concentration, ongoing therapeutic efforts should be based on multiple interventions at different levels. By modification of the acute gene expression induced by ischemia or the apoptotic gene program, gene therapy is a promising treatment but is still in a very experimental phase. Some hurdles will have to be overcome before these therapies can be introduced into human clinical stroke trials.
authors.affiliation: Neurology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. mmillan.germanstria@gencat.net
authors.forename: Mónica
authors.initials: M
authors.lastname: Millán
authors.forename: Juan
authors.initials: J
authors.lastname: Arenillas
mesh_terms: D042501:Angiogenic Proteins / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002545:Brain Ischemia / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002118:Calcium / Q000378:metabolism; D002548:Cerebral Revascularization / Q000379:methods; D002560:Cerebrovascular Circulation; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D027342:Excitatory Amino Acid Transporter 2 / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation; D015316:Genetic Therapy; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019831:Sodium-Calcium Exchanger / Q000235:genetics / Q000378:metabolism; D020521:Stroke / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015533:Transcriptional Activation
chemical_list: D042501:Angiogenic Proteins; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D027342:Excitatory Amino Acid Transporter 2; D018696:Neuroprotective Agents; D019831:Sodium-Calcium Exchanger; D018698:Glutamic Acid; D002118:Calcium